Pfizer Inc. (NYSE:PFE) Stake Lowered by Keystone Financial Planning Inc.

Keystone Financial Planning Inc. decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 0.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 256,187 shares of the biopharmaceutical company’s stock after selling 512 shares during the period. Pfizer accounts for approximately 2.1% of Keystone Financial Planning Inc.’s portfolio, making the stock its 12th biggest position. Keystone Financial Planning Inc.’s holdings in Pfizer were worth $6,797,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Future Financial Wealth Managment LLC increased its position in Pfizer by 5.6% in the 4th quarter. Future Financial Wealth Managment LLC now owns 14,133 shares of the biopharmaceutical company’s stock worth $375,000 after purchasing an additional 753 shares during the last quarter. Talbot Financial LLC boosted its stake in shares of Pfizer by 4.5% during the 4th quarter. Talbot Financial LLC now owns 318,954 shares of the biopharmaceutical company’s stock worth $8,462,000 after acquiring an additional 13,752 shares in the last quarter. Adams Asset Advisors LLC boosted its stake in shares of Pfizer by 10.6% during the 4th quarter. Adams Asset Advisors LLC now owns 342,146 shares of the biopharmaceutical company’s stock worth $9,077,000 after acquiring an additional 32,802 shares in the last quarter. CHICAGO TRUST Co NA boosted its stake in shares of Pfizer by 11.8% during the 4th quarter. CHICAGO TRUST Co NA now owns 41,749 shares of the biopharmaceutical company’s stock worth $1,108,000 after acquiring an additional 4,400 shares in the last quarter. Finally, Kieckhefer Group LLC bought a new stake in shares of Pfizer during the 4th quarter worth about $93,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on PFE. Wolfe Research initiated coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 target price for the company. UBS Group lowered their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Citigroup assumed coverage on shares of Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 target price for the company. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Finally, Guggenheim cut their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Trading Up 0.2 %

PFE stock traded up $0.05 during midday trading on Monday, reaching $26.77. The company’s stock had a trading volume of 19,993,457 shares, compared to its average volume of 33,240,742. The business’s 50-day simple moving average is $26.18 and its 200-day simple moving average is $28.04. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The stock has a market cap of $151.71 billion, a PE ratio of 36.18, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. During the same quarter in the previous year, the business earned ($0.17) EPS. The firm’s revenue was up 31.2% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.43%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is 232.43%.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.